
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
Key Takeaways
- Regulatory review targets a potential first approved combination regimen in myelofibrosis, addressing persistent unmet need beyond JAK inhibitor monotherapy.
- SENTRY enrolled intermediate-1/high-risk, symptomatic, JAK inhibitor–naïve patients with platelets >100×10⁹/L and spleen volume ≥450 cm³, randomizing 2:1 to selinexor 60 mg weekly.
The FDA has accepted a supplemental new drug application (sNDA) seeking the approval of selinexor (Xpovio) plus ruxolitinib (Jakafi) in patients with myelofibrosis.1
The application holds a Prescription Drug User Fee Act target action date of June 28, 2027.
Findings showed that at week 24, a spleen volume reduction of at least 35% (SVR35) occurred in 49.8% of patients receiving selinexor plus ruxolitinib (n = 235) vs 28.0% receiving placebo plus ruxolitinib (n = 118; odds ratio, 2.58; 95% CI, 1.60-4.17; P < .0001).2 The coprimary end point of absolute change in total symptom score (TSS) from baseline to week 24 was not met, although clinically meaningful changes were observed in both arms. The adjusted mean changes were −9.9 vs −10.9, respectively (difference, 0.97; 95% CI, –1.07 to 3.02; P = .825).
"[Patients with] myelofibrosis continue to face a significant unmet need, with JAK inhibitors as the only approved class of therapy," Reshma Rangwala, MD., PhD, chief medical officer and head of Research at Karyopharm Therapeutics, stated in a news release.1 "Selinexor offers a differentiated mechanism of action and, if approved, selinexor plus ruxolitinib could become the first approved combination therapy for patients with myelofibrosis. We look forward to working with the FDA throughout the review process to advance a potential selinexor combination to patients with myelofibrosis."
How was the SENTRY trial designed?
SENTRY was a global, double-blind, randomized, placebo-controlled study that enrolled adult patients with primary, post–essential thrombocythemia, or post–polycythemia vera myelofibrosis who had not previously received a JAK inhibitor.2 Patients needed to have a platelet count above 100 × 10⁹/L. Enrolled patients also needed intermediate-1, intermediate-2, or high-risk disease per the Dynamic International Prognostic Scoring System; symptomatic disease, defined as a symptom score of at least 5 or a TSS of at least 12; and a spleen volume of 450 cm³ or greater.
Patients were randomly assigned 2:1 to receive selinexor at 60 mg orally once weekly or matching placebo, both in combination with ruxolitinib, started at 15 or 20 mg twice daily depending on platelet count, in 28-day cycles.
SVR35 at week 24 and the absolute mean change in TSS from baseline to week 24 served as coprimary end points. Overall survival (OS) and progression-free survival were among the secondary end points.
At the ASCO data readout, meaningful OS outcomes were reported with the experimental combination. At a median follow-up of 11.6 months in the selinexor arm and 12.6 months in the placebo arm, the rates of OS events were 4.7% and 10.2%, respectively (HR, 0.43; 95% CI, 0.19-1.00; nominal P = .022).
What safety findings were reported?
Grade 3 or higher treatment-emergent adverse effects (TEAEs) were reported in 70.1% of patients in the selinexor arm (n = 234) vs 50.0% of those in the control arm (n = 116). Rates of serious TEAEs were 26.9% vs 24.1%, respectively, and AEs led to treatment discontinuation at respective rates of 14.5% vs 8.6%. Fatal AEs occurred in 0.9% of patients in the selinexor arm vs 2.6% of patients in the placebo arm. Investigators deemed none related to study treatment.
Notably, transformation to acute myeloid leukemia occurred in 1.7% of patients in both arms.
“FDA acceptance of our sNDA is a significant milestone in the development of selinexor for patients with myelofibrosis and marks an important step toward expanding selinexor's impact and reach,” Richard Paulson, president and chief executive officer of Karyopharm Therapeutics, stated in a news release.1 "I want to thank our employees for their persistence, dedication and extraordinary commitment, which have brought us to this milestone. Building on our established commercial experience, our teams are actively preparing for a potential launch, with a goal of bringing selinexor plus ruxolitinib to myelofibrosis patients as quickly as possible, if approved."
References
- Karyopharm announces FDA acceptance of supplemental new drug application for Xpovio (selinexor) plus ruxolitinib for the treatment of patients with myelofibrosis. News release. Karyopharm Therapeutics. November 17, 2026. Accessed November 17, 2026. https://investors.karyopharm.com/2026-11-17-Karyopharm-Announces-FDA-Acceptance-of-Supplemental-New-Drug-Application-for-XPOVIO-R-selinexor-Plus-Ruxolitinib-for-the-Treatment-of-Patients-with-Myelofibrosis
- Mascarenhas J, Ali H, Al-Ali H, et al. Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial. J Clin Oncol. 2026;44(suppl 17):LBA6500. doi:10.1200/jco.2026.44.17_suppl.LBA6500
- Bose P, Ali H, Al-Ali HK, et al. Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial. J Clin Oncol. 2026;44(22):2098-2109. doi:10.1200/JCO-26-01080
Related to this article








